As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator(s)

Michael S. Saag, MD

Associate Dean for Global Health, School of Medicine; Jim Straley Chair in AIDS Research; Director, Center for AIDS Research, University of Alabama at Birmingham, Birmingham, Alabama

Disclosures

Disclosure: Michael S. Saag, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.; Merck & Co., Inc.
Received grants for clinical research from: AbbVie Inc.; Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Merck & Co., Inc.; ViiV Healthcare

Dr Saag does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Saag does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Demetre C. Daskalakis, MD, MPH

Assistant Commissioner, NYC Department of Health and Mental Hygiene, Long Island City, New York

Disclosures

Disclosure: Demetre C. Daskalakis, MD, MPH, has disclosed no relevant financial relationships.

Dr Daskalakis does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Daskalakis does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Christian B. Ramers, MD, MPH, AAHIVS

Assistant Medical Director, Research/Special Populations; Director, Graduate Medical Education;

Disclosures

Disclosure: Family Health Centers of San Diego; Clinical Assistant Professor, UC San Diego School of Medicine, San Diego, California Christian B. Ramers, MD, MPH, AAHIVS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Pacific AIDS Education and Training Center (AETC); University of New Mexico Project ECHO
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals
Received grants for clinical research from: California HIV Research Project; California Department of Public Health

Dr Ramers does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Ramers does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Dawn K. Smith, MD, MS, MPH

Biomedical Intervention Implementation Officer, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

Disclosures

Disclosure: Dawn K. Smith, MD, MS, MPH, has disclosed no relevant financial relationships.

Dr Smith does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Smith does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Stacey J.P. Ullman, MHS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Stacey J.P. Ullman, MHS, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

CME / CE

Preventing HIV Infection in the Primary Care Setting: The Role of Pre-Exposure Prophylaxis (PrEP)

Authors: Michael S. Saag, MD; Demetre C. Daskalakis, MD, MPH; Christian B. Ramers, MD, MPH, AAHIVS; Dawn K. Smith, MD, MS, MPH
CME / CE Released: 9/20/2016; Reviewed and Renewed: 11/16/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/16/2018, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for primary care physicians, ID/HIV specialists, nurses, and public health & preventive medicine specialists.

The goal of this activity is to discuss the use of PrEP in the primary care setting, including patient assessment and management, CDC guidelines, and tips for incorporating this into practice.

Upon completion of this activity, participants will be able to:

Discuss the role of pre-exposure prophylaxis (PrEP) in preventing HIV infection
Summarize key recommendations of the CDC's PrEP guidelines
Identify strategies to integrate use of PrEP in the primary care setting for patients at risk of HIV

Disclosures

Moderator(s)

Michael S. Saag, MD

Associate Dean for Global Health, School of Medicine; Jim Straley Chair in AIDS Research; Director, Center for AIDS Research, University of Alabama at Birmingham, Birmingham, Alabama

Disclosures

Disclosure: Michael S. Saag, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.; Merck & Co., Inc.
Received grants for clinical research from: AbbVie Inc.; Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Merck & Co., Inc.; ViiV Healthcare

Dr Saag does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Saag does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Demetre C. Daskalakis, MD, MPH

Assistant Commissioner, NYC Department of Health and Mental Hygiene, Long Island City, New York

Disclosures

Disclosure: Demetre C. Daskalakis, MD, MPH, has disclosed no relevant financial relationships.

Dr Daskalakis does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Daskalakis does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Christian B. Ramers, MD, MPH, AAHIVS

Assistant Medical Director, Research/Special Populations; Director, Graduate Medical Education;

Disclosures

Disclosure: Family Health Centers of San Diego; Clinical Assistant Professor, UC San Diego School of Medicine, San Diego, California Christian B. Ramers, MD, MPH, AAHIVS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Pacific AIDS Education and Training Center (AETC); University of New Mexico Project ECHO
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals
Received grants for clinical research from: California HIV Research Project; California Department of Public Health

Dr Ramers does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Ramers does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Dawn K. Smith, MD, MS, MPH

Biomedical Intervention Implementation Officer, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

Disclosures

Disclosure: Dawn K. Smith, MD, MS, MPH, has disclosed no relevant financial relationships.

Dr Smith does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Smith does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Stacey J.P. Ullman, MHS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Stacey J.P. Ullman, MHS, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Accreditation Statements

Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For Nurses

Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Public Health & Prevention

CME / CE

Preventing HIV Infection in the Primary Care Setting: The Role of Pre-Exposure Prophylaxis (PrEP)

Authors: Michael S. Saag, MD; Demetre C. Daskalakis, MD, MPH; Christian B. Ramers, MD, MPH, AAHIVS; Dawn K. Smith, MD, MS, MPHFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 9/20/2016; Reviewed and Renewed: 11/16/2017

Valid for credit through: 11/16/2018, 11:59 PM EST

processing....

Page 1 of 2

CME / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Faculty and Disclosures

Moderator(s)

Michael S. Saag, MD

Panelist(s)

Demetre C. Daskalakis, MD, MPH

Christian B. Ramers, MD, MPH, AAHIVS

Dawn K. Smith, MD, MS, MPH

Editor(s)

Stacey J.P. Ullman, MHS

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

CME / CE

Preventing HIV Infection in the Primary Care Setting: The Role of Pre-Exposure Prophylaxis (PrEP)

Target Audience and Goal Statement

Disclosures

Moderator(s)

Michael S. Saag, MD

Panelist(s)

Demetre C. Daskalakis, MD, MPH

Christian B. Ramers, MD, MPH, AAHIVS

Dawn K. Smith, MD, MS, MPH

Editor(s)

Stacey J.P. Ullman, MHS

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Preventing HIV Infection in the Primary Care Setting: The Role of Pre-Exposure Prophylaxis (PrEP)